Anna Cameron

Anna Cameron Email and Phone Number

US and Global Market Access and Pricing Expert @ Not Applicable
Anna Cameron's Location
Lansdale, Pennsylvania, United States, United States
Anna Cameron's Contact Details
About Anna Cameron

HEALTH CARE PROFESSIONAL with diverse career that spans global market access, marketing, product development, and sales across entire product life cycle of Pharmaceutical, Vaccine, and Service (Hospital Transition in Care, HTiC) businesses. Knowledgeable regarding application of new healthcare regulations in managed care product planning, commercialization, and pricing / reimbursement. Delivers multi-million dollar business results across markets and divisions in matrix environment. Strong collaborator recognized for innovative, strategic, and analytical thinking. Certified as Executive Black Belt.

Anna Cameron's Current Company Details
Not Applicable

Not Applicable

View
US and Global Market Access and Pricing Expert
Anna Cameron Work Experience Details
  • Not Applicable
    Semi Retired
    Not Applicable Jul 2024 - Present
    Anytown, Ca, Us
    View
  • Sanofi
    Global Market Access And Pricing Team Lead Sarclisa
    Sanofi Oct 2022 - Jul 2024
  • Sanofi Genzyme
    Global Value And Access Lead Oncology
    Sanofi Genzyme Apr 2020 - Jul 2024
    Paris, France, Fr
    View
  • Sanofi Genzyme
    Global Market Access And Pricing Breast Cancer And Early Asset Lead
    Sanofi Genzyme Dec 2020 - Dec 2022
    Paris, France, Fr
    View
  • Mallinckrodt Pharmaceuticals
    Senior Director, Global & New Products Market Access
    Mallinckrodt Pharmaceuticals Jan 2019 - Apr 2020
    Dublin, Ireland, Ie
    View
  • Gsk
    Market Access & Healthcare Solutions Leader Oncology/Hematology
    Gsk Nov 2016 - Dec 2018
    Brentford, Middlesex, Gb
    View
  • Kantar Health
    Senior Director, Market Access And Commercial Strategies
    Kantar Health Apr 2016 - Oct 2016
    New York, New York, Us
    Provided custom and syndicated consulting services to create and successfully implement global market access and commercial strategies for biopharmaceutical assets. Specialize in global market access and US Managed Markets strategies across Oncology, including Hematology, and Specialty Therapeutic areas.
    View
  • Bristol-Myers Squibb
    Director Value And Access Hematology
    Bristol-Myers Squibb May 2015 - Apr 2016
    Lawrence Township, Nj, Us
    In coordination with all relevant functions and geographies, lead development of annual Market Access strategy and tactical planning for I/O product EMPLICITI to drive accelerated reimbursement while maintaining asset value. 
    View
  • Bristol-Myers Squibb
    Director Global Market Access Cv
    Bristol-Myers Squibb Feb 2013 - May 2015
    Lawrence Township, Nj, Us
    With Alliance partner, led development / communication of unified Global Payer Access strategy, value messages and resources for ELIQUIS. Effectively navigated matrix across Alliance to develop/ maintain relationships with HEOR, Market Access colleagues, therapeutic area Development Teams, and other key stakeholders.- Led Alliance (BMS/Pfizer) Market Access Team supporting global access efforts and payer negotiations achieving Access on time or ahead of plan >90% of markets while consistently implementing pricing GOA- Developed additional LCM opportunity which achieved Faster WW Patient Access while maintaining asset value through clear well researched strategy and flawless/disciplined local implementation- Leveraged real-world, HECON data and LCM opportunity to gain preferred status with National payers in France (AFiB), UK NICE, SMC, Quebec, and gain GBA reimbursement for VTE extended treatment w/out added benefit.- Supported CV development team and partnered cross-functionally with other HEOR and commercial sub-teams.- Built/maintained solid command of external trends through advisory boards, conferences, relationships, and competitive intelligence. Synthesize with input from Medical Affairs, Health Economic & Outcomes Research, Regional Access, and Market Research to analyze trends or changes impacting current /future Market Access
    View
  • Merck
    Global Operations/Product Development /Reimbursement Leader, Innovative Ventures Unit: Hospital Tran
    Merck Mar 2010 - Dec 2012
    Managed team of 3 Marketing Managers, consultants, and cross functional support staff to develop the Business to Business Strategy, Go-to-Market framework, reimbursement strategy and partnerships with Hospitals to secure implementation of an outcome study for technology balanced service which seeks to help Hospitals reduce CMS penalties associated with Hospital 30-day readmissions. Co-led completion of detailed P&LConceptualized and completed business plan supporting US Hospital Transitions-in-Care (HTiC) service business; secured corporate venturing funding for 2011, and implemented according to critical success factors by phase gate. •Secured and on-boarded internal resources and external partners to support business plan pilot.Led cross functional team of 3 direct reports, extended support staff, external partners (IBM) and Vendors (HMI, Telerx) to pilot the concept by building the Service, securing customers for a pilot, and creating a clinical program to measure its effectiveness, while securing IRB approval at three hospitals -- in 9 months•Leveraged Merck network to register Service as Merck’s first Class 1 Medical Device through Merck Regulatory •Directed development of Service Life Cycle Plan which was aligned pertinent aspects of the Accountable Care Act•Led Service Reimbursement Framework, Public Policy, and UNC Outcome Study supporting Merck's first corporate venturing initiative US Hospital Transition-in-Care (HTiC) Service •Developed payer validation and reimbursement framework for Hospitals and Health Plans•Oversaw pricing strategy development: Initiated and led development of positive OIG opinion supporting Service Business model and Pricing•Managed development of Hospital and GPO discount strategy, contracting framework, process, and compliance.•Ensured team activities aligned with customer needs, complex FDA and commercial legal regulations
  • Merck
    Global Market Access Special Assignment
    Merck 2012 - 2012
    •Led cross functional team to develop a competitive Global market access strategy framework for Hypertension Compound aimed at delivering product differentiation to the most relevant payers•Achieved Payer and Marketing alignment using Value and Label as Driver (VLAD) process and Stage 0/Phase 2B Global Market Access review resulting in payer value proposition, market access strategy including HTA needs, and market access forecast assumptions•Payer Value Proposition included, but not limited to, clinical endpoints, comparator, outcome measures, QOL instruments and HECON data.
  • Merck
    Global Adherence Leader
    Merck Mar 2009 - Mar 2010
    Global Adherence Leader (2009 – 2010)Led team of 3 Managers/Associate Directors to develop and implement Merck's global adherence capability which is focused on ensuring patients achieve an optimal clinical outcome. Approach allowed Merck to capture unrealized revenue due to medication non-adherence, as well as creating and demonstrating value for healthcare professionals, payer and HTA customers globally through improving patient outcomes and optimizing healthcare expenditures •Developed robust strategy to position Merck as a leader in developing evidenced based adherence solutions•Led business plan development, operating model and general requirements for long term success•Completed benchmarking of adherence activities through external stakeholders and associated activities•Led development of generalized adherence outcomes research plan for chronic care products through an integrated internal advisory board which included members from MRL, Global Outcomes Research, and USOR. This plan was the result of extensive collaboration and consensus building across many functions and divisions.•Created organizational awareness across Merck (Research, Franchises and markets) of the Adherence Platform through systematic outreach to gain input and support to consolidate (and hence reduce) overall vendor spending on interventions within market to rapidly build a broad experience base•Coordinated the development of new adherence-related business opportunities through partnerships with Franchise markets (UK Alliance Boots, MSD Informatics, and ID Franhise (HIV solutions))•At customer request, continued to lead contracting efforts with EmblemHealth (combination HIPNY, GHI). As a result, the commercial contract was extended through 2012, and Tier 2 formulary status of JANUVIA, JANUMET and SINGULAIR with 230,000 Connecticare members was achieved
  • Merck
    Payer Strategist, Us
    Merck 2008 - 2009
    Developed short and long term strategy for Commercial segment and Self Funded Employers to enhance profitable market access, shape benefit design, ensure appropriate utilization, and optimally place solutions to achieve revenue, income, expense, and infrastructure targets for key brands and vaccines. •Supported translation of Commercial and Employer strategy to execution as requested by Customer Sales.•Led initiatives to enhance US Payer knowledge of Medical Benefit to support Merck vaccines.•Delivered desired customer experience though aligning brand strategy with desired customer experience by improving the incorporation of the customer’s perspective in strategy and customer solution development. •At customer request, continued leading contracting with EmblemHealth (combination HIPNY, GHI). As a result, formulary position for ISENTRESS was improved without a discount and market share increased 40% (8/09).
  • Merck
    Senior Director, Customer Marketing Merck Vaccine Division
    Merck 2007 - 2008
    Led team of 3 Managers/Associate Directors in the development of Managed Care brand strategies and tactics to maintain coverage of infant, adolescent and adult vaccines, and ensure profitable product access of HIV products, and achieve disease management outreach objectives for GARDASIL, ZOSTAVAX and ROTATEQ in the Commercial, Managed Medicaid, FFS Medicaid, and Medicare D segments and with Employers. •Led development (4Q07) and implementation (1Q08) of MC Disease Management outreach strategy which resulted in YTD 7/31/08 outreach of 83% to plan with full year estimated actual of 100–150%•Sponsored MVID Service Agreement (SA) Sigma project which reduced contracting time by 42%, while enhancing placement rates 7-fold. Incremental net revenue, including cost reductions associated with reduced contract time, increased by $1.61M 2008/2007. One of three MVID 2008 Merck Sigma Award Submissions.•Oversaw development (1Q08) and implementation (2Q08) of Employer strategy and tactics to enhance benefit designs for GARDASIL which resulted in 7-plans, including Humana and Aetna, changing 2009 benefit design by reducing or eliminating co-pay costs for GARDASIL for women older than 18 years of age.•Oversaw development of vaccine contracting strategies and account management at Kaiser which was 124% to plan YTD 7/31/08. Successfully renegotiated a 2 year contract for ROTATEQ and Value Based Offering for GARDASIL despite pending in-class competition and numerous supply issues for other Merck vaccines•At customer request, maintained contracting responsibility for EmblemHealth (GHI/HIPNY). As a result, the formulary status of SINGULAIR was improved and MAXALT (tablets and MLT) were added to the GHI formulary enhancing NPV by $3.4M (PI 3.4) and $0.3M (PI 1.8), respectively•Recipient: 2007 Managed Care Inspire Award, Winner 2007 Marketing Award for Best Managed Care Program.
  • Merck
    Director Customer Marketing, Ushh Managed Care Division
    Merck 2006 - 2007
    Developed account specific strategies to ensure profitable market access maximizing net sales for full Merck product line with challenging customer base. (Coventry, HIPNY, IBC, AmeriHealth Mercy Plans)•Maintained or enhanced formulary position of SINGULAIR at targeted accounts at current or reduced discounts•Achieved formulary access for JANUVIA and JANUMET in 80% of plans, PBM's, and lives w/in 6 of launch•Led Managed Medicaid Team to develop and gain Marketing approval of segment specific contracting and resource strategies for SINGULAIR, EMEND and JANUVIA enhancing/maintaining the formulary status of SINGULAIR by 35%, and achieving Tier 2 access in 80% of lives for JANUVIA at launch.•Developed and executed post-patent contracting at HIPNY resulting in 76% ZOCOR share through 12/06•Developed and executed post-patent contracting at HIPNY resulting in 76% ZOCOR share through 12/06•2006 Managed Care Rookie of the Year; Finalist 2006 Marketing Awards Best Managed Care program
  • Merck
    Senior Director Marketing, Hypertension Franchise Business Group
    Merck 2003 - 2006
    Led franchise team of 4 Marketing Managers/Associate Directors in the development of market and customer segmentation strategy, promotional resources, medical education and clinical research initiatives for COZAAR/HYZAAR and developmental compounds resulting in annual sales in excess of $1.5B within the US.•Directed the creative development of direct and indirect selling resources and ensured successful field sales implementation for Quality Customer Selling (QCS) and Forward Segmentation (2005). •Developed plan and obtained approval to reallocate excess selling capacity to COZAAR/HYZAAR in 2005 and 2006 and worked with sales teams to achieve market share stabilization in 2005 and first half 2006.•Worked with Merck Research Labs to outline Clinical Development Plans and Sequence Growth opportunities. •U.S. working member of the HTN Global Marketing and Worldwide Business Strategy teams.•Worked with the Medicaid team to develop new competitive pricing which resulted in COZAAR being maintained on 90% of state PDLs (incl. 18 of the 20 largest states) saving $65M in net sales.•Developed Medicare D contracting strategy for COZAAR/HYZAAR gaining profitable access on 10 of 10 PDP's•Worked with VA/DOD team to develop pricing strategy which won the VA National ARB solicitation and oversaw marketing initiatives supporting immediate contract execution increasing market share three fold. •Finalist for 2004 Merck Marketing Awards: US and Worldwide Sequence Growth, Best Innovation.•Finalist for 2005 Merck Marketing Awards: Worldwide Franchise of the Year.
  • Merck
    Marketing Director, New Products And Oncology Franchise Business Groups
    Merck 2000 - 2003
    Responsible for development and execution of scientific, clinical strategies to support the launch of EMEND.•Led development and execution of scientific and promotional strategies from Phase 2 to launch.•Collaborated with Merck Research Labs, Global Team and various committees to outline clinical development plan, develop and negotiate PI and PPI for EMEND and address Phase IV commitments. •NDA submission and FDA approval achieved ahead of plan due to aggressive clinical program management.•Completed initial Statement of Interest (SOI) for EMEND IV. •Led MMD activities for innovative packaging and ensured product availability 10 days post approval.•Completed market assessment and developed strategy for entering the Oncology market.•Led successful organizational sell-in, deployment, training, strategic/tactical direction for Oncology Health Science Associates, a new sales team established for the Oncology Franchise Business Unit. •Successfully led activities for Business Plan, Profit Plan in 2000 and 2001.•Collaborated with Public and Economic Affairs, to develop preliminary pricing and reimbursement strategies.•Finalist Merck Marketing Awards: Best Physician Program, Lifecycle Management, Product Planning.
  • Merck
    Business/Sales Manager
    Merck 1997 - 2000
    Managed 13 Representatives calling on Primary Care and Specialty physicians to achieve above plan performance of 102% and 101% in 1998 and 1999, respectively. •Successfully launched SINGULAIR. District sales and market share performance highest in Region.•Successfully launched VIOXX. District market share highest in Region and fourth in Region Business Group•Recipient Most Valuable Peer Award in 1998 and 1999.
  • Merck
    Marketing Manager, Hypertension And Heart Failure Therapeutic Business Group
    Merck 1995 - 1997
    Developed marketing and promotional strategies to support revenue growth of PRINIVIL/PRINZIDE which resulted in meeting or exceeding US sales objectives in excess of $500M.
  • Merck
    Manager, Innovative Marketing
    Merck Jun 1994 - Nov 1995
    Developed marketing and promotional strategies to support launch and revenue growth of Adherence program.
  • Merck
    Promotion Manager
    Merck Mar 1993 - Jun 1994
    Responsible for creating and implementing traditional as well as non-traditional promotional strategies and programs for PRIMAXIN and MEFOXIN. Received Management Award and Customer Hero Status.
  • Merck
    Field Communications Coordinator
    Merck May 1992 - Mar 1993
  • Merck Sharp & Dohme
    Hospital Sales Representative
    Merck Sharp & Dohme Sep 1989 - May 1992

Anna Cameron Skills

Managed Care Pharmaceutical Industry Cross Functional Team Leadership Oncology Market Access Hospital Sales Pharmaceutical Sales Strategy Product Launch Urology Global Marketing Commercialization Diabetes Vaccines Sales Effectiveness Medical Devices Marketing Strategy Clinical Trials Gastroenterology Leadership Cardiology Management Neurology Product Development Infectious Diseases Rheumatology Pharmacovigilance Six Sigma Asthma Anti Infectives Adult Vaccines Pediatric Vaccines Adolescent Vaccines Self Pay Market Us Managed Markets Va/dod Commercial Managed Care Innovation

Anna Cameron Education Details

  • Fox School Of Business At Temple University
    Fox School Of Business At Temple University
    Health Care Administration
  • Rochester Institute Of Technology
    Rochester Institute Of Technology
    Medical Technology
  • Rochester General Hospital School Of Medical Technology
    Rochester General Hospital School Of Medical Technology
    Clinical Laboratory Science/Medical Technology/Technologist
  • Rochester Institute Of Technology
    Rochester Institute Of Technology
    Clinical Laboratory Science/Medical Technology/Technologist

Frequently Asked Questions about Anna Cameron

What company does Anna Cameron work for?

Anna Cameron works for Not Applicable

What is Anna Cameron's role at the current company?

Anna Cameron's current role is US and Global Market Access and Pricing Expert.

What is Anna Cameron's email address?

Anna Cameron's email address is an****@****ast.net

What schools did Anna Cameron attend?

Anna Cameron attended Fox School Of Business At Temple University, Rochester Institute Of Technology, Rochester General Hospital School Of Medical Technology, Rochester Institute Of Technology.

What skills is Anna Cameron known for?

Anna Cameron has skills like Managed Care, Pharmaceutical Industry, Cross Functional Team Leadership, Oncology, Market Access, Hospital Sales, Pharmaceutical Sales, Strategy, Product Launch, Urology, Global Marketing, Commercialization.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.